Immunotherapy revolutionizes frontline treatment in advanced RCC

March 25, 2021
Urology Times staff

Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.